Carpenter CCJ, Fischl MA, Hammer SM.
et al. Antiretroviral therapy for HIV infection in 1998. JAMA.1998;280:78-86.
Fätkenheuer G, Thiesen A, Rockstroh J.
et al. Virological treatment failure of protease inhibitor therapy in an unselected
cohort of HIV-infected patients. AIDS.1997;11:F113-F116.
Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment
failure in patients with HIV starting a protease inhibitor. AIDS.1998;12:2161-2167.
Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine, and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med.1997;337:734-739.
Wein LM, D'Amato RM, Perelson AS. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication
or maintenance of low viral loads. J Theor Biol.1998;192:81-98.
Havlir DV, Marschner IC, Hirsch MS.
et al. Maintenance antiretroviral therapies in HIV-infected subjects with
undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med.1998;339:1261-1268.
Condra JH, Schleif WA, Blahy OM.
et al. In vivo emergence of HIV-1 variants resistant to multiple protease
Molla A, Korneyeva M, Gao Q.
et al. Ordered accumulation of mutations in HIV protease confers resistance
to ritonavir. Nat Med.1996;2:760-766.
Ho DD, Toyoshima T, Mo H.
et al. Characterization of human immunodeficiency virus type 1 variants with
increased resistance to a C2-symmetric protease inhibitor. J Virol.1994;68:2016-2020.
Gulnik SV, Suvorov LI, Liu B.
et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease
mutants selected under drug pressure. Biochemistry.1995;34:9282-9287.
Nijhuis M, Schuurman R, de Jong D.
et al. Selection of HIV-1 variants with increased fitness during ritonavir
therapy. In: International Workshop on HIV Drug Resistance, Treatment Strategies
and Eradication; June 25-28, 1997; St Petersburg, Fla. Abstract 92.
Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency
virus type 1. J Virol.1998;72:7632-7637.
Little SJ, Daar ES, D'Aquila RT.
et al. Reduced antiretroviral drug susceptibility among patients with primary
HIV infection. JAMA.1999;282:1142-1149.
Hellmann N, Johnson P, Petropoulos C. Validation of the performance characteristics of a novel, rapid phenotypic
drug susceptibility assay: PhenoSense HIV. In: Programs and abstracts of the 3rd International Workshop on Drug
Resistance and Treatment Strategies; June 23-26, 1999; San Diego, Calif. Abstract
Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative performance of high-density oligonucleotide sequencing
and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses.1998;14:869-876.
Hirsch MS, Conway B, D'Aquila RT.
et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA.1998;279:1984-1991.
Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and
multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med.1998;128:906-911.
Condra JH, Holder DJ, Schleif WA.
et al. Genetic correlates of in vivo viral resistance to indinavir, a human
immunodeficiency virus type 1 protease inhibitor. J Virol.1996;70:8270-8276.
Young B, Johnson S, Bahktiari M.
et al. Resistance mutations in protease and reverse transcriptase genes of
human immunodeficiency virus type 1 isolates from patients with combination
antiretroviral therapy failure. J Infect Dis.1998;178:1497-1501.
Mayers DL, Gallahan DL, Martin GJ.
et al. Drug resistance genotypes from plasma virus of HIV-infected patients
failing combination drug therapy. In: International Workshop on HIV Drug Resistance, Treatment Strategies
and Eradication; June 25-28, 1997; St Petersburg, Fla. Abstract 80.
Holder DJ, Condra JH, Schleif WA, Chodakewitz J, Emini EA. Virologic failure during combination therapy with Crixivan and RT inhibitors
is often associated with expression of resistance-associated mutations in
RT only. In: 6th Conference on Retroviruses and Opportunistic Infections;
January 31 to February 4, 1999; Chicago, Ill. Abstract 492.
Descamps D, Peytavin G, Calvez V.
et al. Virologic failure, resistance and plasma drug measurements in induction
maintenance therapy trial (Anrs 072, Trilege). In: 6th Conference on Retroviruses and Opportunistic Infections;
January 31 to February 4, 1999;Chicago, Ill. Abstract 493.
Richman D, Shih CK, Lowy I.
et al. Human immunodeficiency virus type 1 mutants resistant to non–nucleoside
inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A.1991;88:11241-11245.
Schinazi RF, Lloyd Jr RM, Nguyen MH.
et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine
nucleosides. Antimicrob Agents Chemother.1993;37:875-881.
Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant
to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse
transcriptase. Proc Natl Acad Sci U S A.1993;90:5653-5656.
Boucher CA, Cammack N, Schipper P.
et al. High-level resistance to enantiomeric 2'-deoxy-3'-thiacytidine in vitro
is due to one amino acid substitution in the catalytic site of human immunodeficiency
virus type 1 reverse transcriptase. Antimicrob Agents Chemother.1993;37:2231-2234.
Schuurman R, Nijhuis M, van Leeuwen R.
et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance
of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis.1995;171:1411-1419.
Wei X, Ghosh SK, Taylor ME.
et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature.1995;373:117-122.
Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus. J Virol.1996;70:7894-7899.
Bacheler L, Weislow O, Snyder S, Hanna G, D'Aquila R. The Sustiva Resistance Study Team: virological resistance to efavirenz. In: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland.
Larder B. Nucleosides and foscarnet mechanisms. In: Richman DD, ed. Antiviral Drug Resistance. Chichester, England: John Wiley & Sons; 1996:169-190.
de Jong MD, Veenstra J, Stilianakis NI.
et al. Host-parasite dynamics and outgrowth of virus containing a single K70R
amino acid change in reverse transcriptase are responsible for the loss of
human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci U S A.1996;93:5501-5506.
Markowitz M, Ho DD. Protease inhibitors—mechanisms and clinical aspects. In: Richman DD, ed. Antiviral Drug Resistance. Chichester, England: John Wiley & Sons; 1996:261-278.
Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple gag and gag-pol processing
defects in human immunodeficiency virus type 1 variants selected for resistance
to protease inhibitors in vivo. J Virol.1998;72:3300-3306.
McLean AR, Nowak MA. Competition between zidovudine-sensitive and zidovudine-resistant strains
of HIV. AIDS.1992;6:71-79.
Lee CG, Gottesman MM, Cardarelli CO.
et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry.1998;37:3594-3601.
Kim RB, Fromm MF, Wandel C.
et al. The drug transporter P-glycoprotein limits oral absorption and brain
entry of HIV-1 protease inhibitors. J Clin Invest.1998;101:289-294.